Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Cell Therapeutics Acquires Zevlin From Biogen Idec
- Cell Therapeutics, Inc. CTI (Nasdaq, MTAX: CTIC), Seattle, has announced that it has completed its acquisition of ZevalinR ibritumomab tiuxetan from Biogen Idec, giving CTI sole responsibility for marketing, sales, and development of the drug in the United States. Zevalin will continue to be sold outside the United States by...
- Research articles 2008-02-01
- Cell Therapeutics completes acquisition of lymphoma drug Zevalin from Biogen Idec for sales and marketing in the United States.
- Cell Therapeutics, Inc. (Seattle, WA) has completed its acquisition of Zevalin ibritumomab tiuxetan from Biogen Idec, giving CTI sole responsibility for marketing, sales, and development of the drug in the United States. Zevalin will continue to be sold outside the United States by Bayer Schering under...
- Research articles 2007-12-01
- Celera Genomics Announces the Sale of Its Cathepsin S Inhibitor Program to Schering AG; Transaction Completes Celera's Planned Exit from Small Molecule Development
- ROCKVILLE, Md. -- Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that Schering AG has acquired its cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases. The financial terms of the transaction include an upfront cash payment of $5 million, half of which is payable...
- Research articles 2006-06-21
- New Data Show Improved Outcomes in Certain Lymphomas With ZEVALIN® Radioimmunotherapy
- ATLANTA -- Abstracts Presented at ASCO Annual Meeting Explore Use of ZEVALIN in First-Line Therapy, Retreatment and Transplant Combinations Biogen Idec Inc. (Nasdaq:BIIB) and Schering AG, Germany (FSE:SCH) (NYSE:SHR) announced new data presented this week at the 42nd American Society of Clinical Oncology ASCO Annual Meeting in Atlanta, Ga.,...
- Research articles 2006-06-06
- EPIX Medical Announces Name Change to EPIX Pharmaceuticals
- CAMBRIDGE, Mass. -- EPIX Medical, Inc. (NASDAQ: EPIX) today announced that it has changed its corporate name to EPIX Pharmaceuticals, Inc. to better reflect its focus on developing pharmaceutical products. EPIX continues to trade on the NASDAQ National Market under the ticker symbol "EPIX". This name change was approved by...
- Research articles 2004-09-07
- Male contraceptive
- Schering AG and Organon Inc. plan to develop a hormone contraceptive for men. Trials for the product, a long-term implant that is accompanied by an injection four times a year, are expected to begin in 2003.
- Research articles 2002-12-16
- Trials for male contraceptive to start next year
- GERMANY: The pharmaceutical companies Schering AG and Organon said yesterday they planned to develop a marketable hormone contraceptive for men within seven years. Trials for the implant - to stop the production of sperm and the hormone testosterone - will start next year.
- Research articles 2002-11-22
- J.P. Morgan announces NYSE listing of Schering AG ADRs
- Business Editors NEW YORK--BUSINESS WIRE--Oct. 12, 2000 J.P. Morgan, as depositary bank, announced today that Schering AG, an international research-based specialty pharmaceutical company, has launched a sponsored American Depositary Receipt ADR facility listed on the New York Stock Exchange. Beginning today, Schering AG ADRs will trade under the...
- Research articles 2000-10-12
- BRADLEY PHARMACEUTICALS Fulfills its Commitment to File Registration Statement for Previously Issued Shares to Berlex Laboratories
- FAIRFIELD, N.J.--BUSINESS WIRE--October 15, 1997--BRADLEY PHARMACEUTICALS, INC. (NASDAQ NM: BPRX) today reported that the 1,450,000 previously issued shares of Class A Common Stock issued to Berlex Laboratories, a subsidiary of Schering AG, have been included for registration under the Securities Act of 1933 as part of a registration statement on...
- Research articles 1997-10-15
- New Capsule
- Ribozyme, Schering Link... RIBOZYME PHARMACEUTICALS Inc. RPI has signed a research collaboration with Schering AG focusing on the use of ribozymes for therapeutic target validation and the development of ribozymes as therapeutic agents. RPI will contribute its ribozyme technology and Berlex Laboratories...
- Research articles 1997-04-21
Additional Resources
- Bayer Schering Pharma AG: Company Profile
- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. Bayer Schering Pharma AG: PharmaVitae Profile http://www.reportlinker.com/p091761/Bayer-Schering-Pharma-AG-PharmaVitae-Profile.html Introduction This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical...
- Research articles 2008-08-12
- Focus on the Bayer Schering Pharma AG: PharmaVitae Profile
- NEW YORK -- Reportlinker.com announces that a new market research report is available in its catalogue. Bayer Schering...
- Research articles 2009-05-06
- Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
- CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ: DYAX) announced today that they have entered into an agreement with Bayer Schering Pharma AG for the discovery of therapeutic antibodies. Under the terms of this agreement, Dyax will identify therapeutic antibodies for two targets provided by Bayer Schering Pharma. Furthermore, these research activities...
- Research articles 2007-09-05
- Reportlinker Adds Bayer Schering Pharma AG: PharmaVitae Profile
- NEW YORK -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds...
- Research articles 2009-07-27
- xCELLigence Cell Analysis System from Roche to Be Used by Bayer Schering Pharma AG
- PENZBERG, Germany -- The xCELLigence System for Realtime non-labeled cell analysis from Roche Applied Science will be used by Bayer Schering Pharma AG, Berlin, Germany as one of the first users of the system. The xCELLigence System is designed for a multitude of applications spanning from short term kinetic analysis,...
- Research articles 2008-10-16
- Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma
- BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate ADC collaboration with Bayer Schering Pharma AG, Germany. The...
- Research articles 2009-09-08
- New step for Bayer Schering.(Bayer AG acquired Schering AG)(Brief article)
- Berlin, Germany-based pharmaceutical company Schering has now been officially renamed Bayer Schering Pharma AG. This is the latest step in the nearly $20 billion dollar acquisition of Schering by Bayer last July, edging out other giants such as Merck. "We are pleased that...
- Research articles 2007-01-01
- Schering renamed
- BUSINESSSchering AG German has been officially renamed Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006, and the new logo has been mounted on Bayer Schering Pharma's headquarters building in Berlin."We are continuing to make good headway with the integration process," said...
- Research articles 2007-02-01
- Bayer to invest 129 mln US dlrs in China drug R&D center
- Bayer to invest 129 mln US dlrs in China drug R&D center BEIJING, Feb. 12 Xinhua -- German pharmaceutical company Bayer said Thursday it would invest 100 million euros (129 million U.S. dollars) within five years to set up a research and development (R&D)...
- Research articles 2009-02-12
- Barr wins patent dispute
- Wall Street predicted drug developer Barr Pharmaceuticals Inc. Woodcliff Lake NJ would gain more revenue from generic sales of the birth-control pill Yasmin following a patent dispute victory last week. The dispute stretches back to 2005, when Barr asked the Food and Drug Administration to approve a generic...
- Research articles 2008-03-10
- << Previous
- page 1 of 1
- Next >>
